Singapore Markets open in 5 hrs 40 mins

Omicron’s rapid spread shreds budding recovery in air travel

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.16+2.77 (+7.22%)
As of 02:19PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close45.94
Bid40.66 x 1100
Ask40.77 x 800
Day's range39.15 - 41.21
52-week range25.31 - 141.01
Avg. volume1,228,358
Market cap5.418B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-14.64
Earnings date06 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est69.86
  • Zacks

    Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron

    Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

  • Motley Fool

    Why Vir Biotechnology Stock Is Soaring Today

    Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.

  • Motley Fool

    Why Vir Biotechnology Is Up More Than 13% Today

    Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. Indeed, headlines regarding the new omicron variant of the coronavirus began to surface before Thursday's Thanksgiving holiday. It just took a while for investors to connect the dots all the way back to Vir Biotechnology, which potentially benefits from a renewed outbreak of infections stemming from this new strain of the pandemic-causing virus.